Sarepta Therapeutics (NASDAQ:SRPT) Receives “Buy” Rating from William Blair

William Blair reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Friday morning, AnalystRatings.com reports.

Other analysts also recently issued reports about the company. BTIG Research set a $190.00 price objective on Sarepta Therapeutics and gave the company a buy rating in a research report on Wednesday, April 17th. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the stock a buy rating in a research report on Monday, June 17th. Royal Bank of Canada increased their target price on Sarepta Therapeutics from $188.00 to $220.00 and gave the stock an outperform rating in a research report on Monday, July 1st. Zacks Investment Research upgraded Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 target price on the stock in a research report on Wednesday, May 8th. Finally, Citigroup reduced their target price on Sarepta Therapeutics from $201.00 to $190.00 and set a buy rating on the stock in a research report on Thursday, May 16th. Two research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. Sarepta Therapeutics currently has an average rating of Buy and a consensus price target of $208.29.

Shares of NASDAQ:SRPT traded down $6.87 on Friday, hitting $126.11. The company had a trading volume of 2,087,729 shares, compared to its average volume of 924,450. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. Sarepta Therapeutics has a 52-week low of $95.21 and a 52-week high of $165.87. The business has a 50 day moving average of $146.13. The firm has a market capitalization of $10.55 billion, a P/E ratio of -23.10 and a beta of 2.01.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 56.64%. The company had revenue of $94.67 million during the quarter, compared to analysts’ expectations of $91.05 million. During the same quarter in the prior year, the company earned ($1.67) earnings per share. The firm’s revenue was up 28.8% compared to the same quarter last year. On average, research analysts predict that Sarepta Therapeutics will post -4.04 EPS for the current fiscal year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director now directly owns 21,717 shares in the company, valued at $2,606,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.60% of the company’s stock.

Large investors have recently made changes to their positions in the business. LPL Financial LLC grew its stake in shares of Sarepta Therapeutics by 26.0% in the second quarter. LPL Financial LLC now owns 16,607 shares of the biotechnology company’s stock valued at $2,523,000 after buying an additional 3,428 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Sarepta Therapeutics by 8.9% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 306,409 shares of the biotechnology company’s stock valued at $46,559,000 after purchasing an additional 24,932 shares in the last quarter. Miramar Capital LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $229,000. New England Private Wealth Advisors LLC grew its stake in Sarepta Therapeutics by 25.5% during the 2nd quarter. New England Private Wealth Advisors LLC now owns 2,494 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 506 shares in the last quarter. Finally, Delek Group Ltd. acquired a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $7,423,000. Institutional investors own 94.72% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Recommended Story: What is a blue-chip stock?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.